Side Effects Drake Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Drake Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Celebrity: Drake (Aubrey Drake Graham)
  • Drug confirmed: Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly injection)
  • Confirmation type: Publicly confirmed via social media in 2023
  • Drug class: GLP-1 receptor agonist
  • Side effects discussed publicly: Gastrointestinal symptoms including nausea and appetite suppression
  • Clinical match: These rank among the top adverse events in the FDA prescribing information for Ozempic

Drake's Public Confirmation: What He Actually Said

In 2023, Drake acknowledged Ozempic use through social media posts, discussing the medication in a casual, matter-of-fact tone. He did not frame it as a medical confession or a dramatic reveal. The posts referenced side effects, particularly gastrointestinal discomfort, and the appetite-suppressing quality of the drug.

This confirmation was notable because, at the time, public GLP-1 discourse skewed heavily toward female celebrities. Drake's openness contributed to a shift in how men discussed weight management medications publicly. Visible body composition changes between 2022 and 2024, widely covered in entertainment media, tracked with the timeline of his confirmed use.

What the HealthRX Medical Team wants to be clear about: Drake's social posts described symptoms. He did not, in any public statement, provide dosing details, treatment duration, or the name of his prescribing physician. Any specifics beyond what he posted remain private medical information, and this page does not speculate beyond the public record.

Nausea: The Side Effect Nearly Every GLP-1 User Knows

Drake referenced nausea in connection with his Ozempic use. This is the single most commonly reported adverse event across every major semaglutide trial.

In the STEP 1 trial (2021, published in the New England Journal of Medicine), which studied semaglutide 2.4 mg weekly for weight management, nausea occurred in 44.2% of participants in the semaglutide group compared to 17.4% in the placebo group. The SUSTAIN 6 cardiovascular outcomes trial reported nausea rates of 20.3% at the 1.0 mg dose.

Nausea with semaglutide is dose-dependent and typically peaks during the titration phase (the first 4 to 8 weeks as the dose increases from 0.25 mg to the target). Most patients report that it diminishes after the body adjusts. The mechanism involves delayed gastric emptying, a core pharmacologic action of GLP-1 receptor agonists, combined with central effects on the area postrema in the brainstem.

For men specifically, the STEP 1 subgroup analysis showed comparable nausea rates across sexes, though the trial enrolled fewer men (about 27% of participants were male). The HealthRX Medical Team notes that men are not "protected" from GI side effects simply because early media coverage focused on women.

Appetite Suppression: Feature or Side Effect?

Drake's posts also touched on a dramatically reduced desire to eat. Whether this qualifies as a side effect or the intended therapeutic action depends on framing, but clinically it warrants discussion.

Semaglutide reduces appetite through two pathways. The peripheral pathway delays gastric emptying, keeping food in the stomach longer and producing a feeling of fullness. The central pathway involves direct activation of GLP-1 receptors in the hypothalamus, specifically in areas regulating hunger and satiety signals. A 2023 neuroimaging study published in The Lancet demonstrated that semaglutide reduces neural responses to food cues in brain regions associated with reward processing.

For someone like Drake, whose public persona involves high-profile dining, events, and social eating, this degree of appetite suppression can carry real quality-of-life implications that go beyond the clinical definition of "decreased appetite" found on the FDA label.

The Full GI Picture: What the FDA Label Lists

Drake's publicly described symptoms sit within a broader gastrointestinal adverse event profile. The Ozempic prescribing information lists these GI events with the following approximate incidence rates at the 1 mg dose:

| Adverse Event | Semaglutide 1 mg | Placebo | |---|---|---| | Nausea | 20.3% | 6.1% | | Diarrhea | 8.5% | 1.9% | | Vomiting | 9.2% | 2.3% | | Constipation | 5.0% | 1.5% | | Abdominal pain | 5.7% | 3.0% |

Drake did not publicly confirm experiencing all of these. The table above provides clinical context so readers can understand the full range of what is common with this medication class.

The HealthRX Medical Team emphasizes that GI events are the primary reason patients discontinue GLP-1 therapy. In STEP 1 to 7.0% of semaglutide patients discontinued due to GI adverse events compared to 3.1% on placebo. Slow dose titration, eating smaller meals, and avoiding high-fat foods are standard mitigation strategies recommended in ADA guidelines.

What Drake Has Not Discussed Publicly

Several clinically significant side effects of semaglutide have not appeared in Drake's public statements, and this page will not attribute them to him. For general clinical awareness, these include:

Pancreatitis risk. The FDA label carries a warning about acute pancreatitis. Post-marketing surveillance and a 2023 meta-analysis in JAMA Internal Medicine found a small but statistically significant increased risk. Symptoms include severe, persistent abdominal pain radiating to the back.

Thyroid C-cell concerns. Semaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumors. The clinical relevance in humans remains uncertain, but it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gallbladder events. Rapid weight loss from any cause increases gallstone risk. SUSTAIN and STEP trial data showed cholelithiasis rates of 1.5% to 2.6% in semaglutide groups.

Muscle mass loss. A concern particularly relevant for men: GLP-1-mediated weight loss includes lean mass reduction alongside fat loss. The STEP 1 body composition substudy found that roughly 39% of total weight lost was lean mass. Resistance training during GLP-1 therapy is widely recommended by endocrinologists to preserve muscle.

GLP-1 Use in Men: The Broader Clinical Picture

Drake's public confirmation matters partly because the GLP-1 clinical trial population has historically skewed female. In the STEP program, approximately 73% of participants were women. This means the side effect profile is better characterized in women, and men's experiences, including Drake's, add to the real-world signal.

A 2022 real-world evidence study found that men on semaglutide reported similar GI side effect rates but were less likely to discuss them with their prescriber. The HealthRX Medical Team considers Drake's willingness to mention side effects publicly a net positive for men's health literacy around this drug class. When a high-visibility male figure says "this medication made me feel nauseous," it normalizes a conversation that clinical data shows men are already having privately.

The HealthRX Medical Team Take

Drake's public record aligns cleanly with what the clinical literature predicts. Nausea and appetite suppression are the two most frequently reported effects of semaglutide, and those are exactly what he described.

What makes his case worth clinical attention is not that his side effects were unusual. They were textbook. The value is that he reported them publicly, as a man, at a time when the cultural conversation about GLP-1 medications was dominated by female celebrity stories. His confirmation helped correct a perception gap: these medications work the same way in male and female patients, the side effects track similarly, and men should expect and prepare for the same GI adjustment period.

For any patient (regardless of celebrity status) starting Ozempic, the HealthRX Medical Team recommends discussing the standard titration schedule with a prescribing physician. Starting at 0.25 mg weekly for four weeks, then increasing to 0.5 mg, allows the GI tract to adapt. Patients who rush to higher doses experience more severe nausea. This is well-documented in the FDA-approved dosing guidance and is not optional.

Frequently asked questions

›
›
›
›

References